Oncorus Inc (ONCR) Quote

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form 15-12G - Securities registration termination [Section 12(g)]

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form 8-K - Current report

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form 8-K - Current report

Oncorus Announces Workforce Reduction Plan

ANDOVER, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), an RNA medicines company focused on developing intravenously administered, self-amplifying RNA to transform...

Oncorus Reports First Quarter 2023 Financial Results and Provides Business Updates

IND submission for ONCR-021 still planned for mid-2023, subject to receipt of additional funding Ended the quarter with $45.0 million in cash, cash equivalents and investments ANDOVER, Mass., May...

Oncorus Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates

Reprioritized product portfolio to focus on IV-administered, self-amplifying RNA medicinesOn track to submit IND for ONCR-021 in mid-2023Preclinical data featured in Nature Communications support...

Oncorus Announces Research Collaboration with Daewoong Pharmaceutical for the Development of Lipid Nanoparticle Formulations for mRNA Drug Candidates

Research collaboration leverages Oncorus’ proprietary ionizable amines, PEG lipids, LNP formulations, process development and manufacturing together with Daewoong’s mRNA expertiseOpportunity for...